# Trade Mark Journal No.2025/040 3 October 2025

## WO0000001876405 (1,5)

Office of origin: United States of America

Date of International Registration:22 July 2025
Date of designation in the UK: 22 July 2025

International priority date claimed: 25 April 2025 (United States of America) (99155128)

Class 1
  Recombinant cytokine proteins for research use; recombinant cytokine proteins for use in manufacture of pharmaceutical products, veterinary preparations, cellular therapies, gene therapies, regenerative medicines, and vaccines; chemicals, namely, non-animal derived cell culture media supplement to promote cell growth, optimization, and productivity; non-animal derived cell culture media supplement to promote cell growth, optimization, and productivity for scientific, laboratory or medical research.
Class 5
  Recombinant cytokine proteins for clinical or pharmaceutical use; recombinant cytokine proteins for therapeutic purposes; recombinant cytokine proteins for the optimization of in vitro expansion of cells; pharmaceutical preparations, namely, cytokine drugs for the optimization of in vitro expansion of cells.

InVitria, Inc.

Representative: Dianne M. Smith-Misemer Hovey Williams LLP, 10801 Mastin Blvd., Suite 1000, Overland Park KS 66210, UNITED STATES OF AMERICA